Exelixis enters into a clinical collaboration for three phase 3 combination trials in advanced solid tumours

This article was originally published here

The clinical program, which will be co-funded by the companies, is expected to include three phase 3 pivotal trials in advanced non-small cell lung cancer (NSCLC), castration-resistant prostate

The post Exelixis enters into a clinical collaboration for three phase 3 combination trials in advanced solid tumours appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply